Advertisement
Screener

MAZE THERAPEUTICS, INC. (MAZE) Cash Flow Breakdown

MAZE THERAPEUTICS, INC. Cash Flow Breakdown

Cash flow breakdown shows where MAZE THERAPEUTICS, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $111.94M went out.
  • Fiscal year ended 2025-12-31: from investing, $170.96M went out.
  • Fiscal year ended 2025-12-31: from financing, $275.34M came in.
  • Fiscal year ended 2025-12-31: change in cash, $7.57M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$111.94M-$170.96M$5.56M$269.78M*-$7.57M
2024-12-31$75.95M-$1.15M$733.00K$92.11M*$167.65M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew debtNew shares soldNot split outChange in cash
2026-06-30-$15.05M*-$128.51M*$0.00*$1.70M*$145.74M*
2026-03-31-$39.11M$6.28M$39.40M$4.08M-$1.12M*$9.52M
2025-12-31-$27.73M*-$103.39M*$3.43M*
2025-09-30-$24.64M*-$66.88M*$2.01M*$141.75M*
2025-06-30-$30.05M*-$393.00K*$0.00*$612.00K*
2025-03-31-$29.52M-$299.00K$126.00K$127.25M*$97.56M
2024-12-31-$22.45M*-$605.00K*$63.00K*$70.20M*
2024-09-30-$23.20M*-$103.00K*$226.00K*-$2.38M*
2024-06-30$145.05M*-$160.00K*$79.00K*
2024-03-31-$23.44M-$279.00K$365.00K$24.22M*$865.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
NOVAVAX INC (NVAX)United States$1.748B-6.26
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81